ScinoPharm Taiwan Ltd
TWSE:1789
Net Margin
ScinoPharm Taiwan Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| TW |
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
17.4B TWD |
10%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.4B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
394B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
233.4B CHF |
20%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
174.8B GBP |
13%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
198.5B CHF |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
225.9B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
13%
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on ScinoPharm Taiwan Ltd's most recent financial statements, the company has Net Margin of 10%.
You don't have any saved screeners yet